AIA Group Ltd Sells 62,937 Shares of Pfizer Inc. (NYSE:PFE)

AIA Group Ltd lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 192,004 shares of the biopharmaceutical company's stock after selling 62,937 shares during the quarter. AIA Group Ltd's holdings in Pfizer were worth $5,094,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. PSI Advisors LLC boosted its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. lifted its position in Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the period. Lipe & Dalton boosted its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC grew its position in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after buying an additional 401 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.82 during midday trading on Tuesday, hitting $24.53. 54,333,514 shares of the stock traded hands, compared to its average volume of 39,155,959. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a market capitalization of $139.09 billion, a P/E ratio of 17.39, a PEG ratio of 0.64 and a beta of 0.61. The firm has a 50-day moving average of $26.05 and a two-hundred day moving average of $26.88.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the firm posted $0.10 earnings per share. The business's revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Truist Financial dropped their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.